MIVT Invited to Lecture on Proprietary Biocompatible Coatings for Implanted Medical Devices and Drug Delivery Systems; Company Scientist Presents Data on Next Generation Coatings and Applications for Localized Treatment of Diseases

Business Wire, March 2, 2006

VANCOUVER, British Columbia -- MIV Therapeutics Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announced that one of its chief scientists presented a lecture at the University of Washington detailing recent research findings on the company's innovative drug delivery systems designed to improve the performance of currently available cardiovascular stents and other implantable medical devices and the targeted treatment of cardiovascular and other chronic diseases. E[acute accent]Prof. Tom Troczynski, VP of Coatings at MIVT presented the lecture entitled "Advances in Hydroxyapatite-Based Bio-Ceramic and Composite Thin Films for Implant Surface Modification and Drug Delivery," to the Faculty of the Department of Materials Science and Engineering at the University of Washington, in Seattle WA, on Feb. 13, 2006. E[acute accent]Prof. Troczynski's presentation focused on the science of wet chemical technologies behind the novel ultra-thin and micro-thin HAp-based bio-ceramic coatings and drug delivery systems that MIVT has developed for cardiovascular stents, other implantable medical devices and localized drug delivery for the treatment of chronic diseases. E[acute accent]MIVT has developed a family of novel HAp-based device coatings and drug delivery systems that provide the highest level of performance, while avoiding or counter-measuring serious medical and biocompatibility problems demonstrated by the coating technologies of current drug delivery systems. A comprehensive range of animal trials by MIVT has confirmed research that MIVT's biocompatible HAp coatings do not trigger the adverse bodily reactions such as restinosis, thrombosis (dangerous blood clotting) and biocompatibility problems that are causing some concern in the medical implantable device marketplace. E[acute accent]Initial studies have confirmed that the HAp polymer-free coatings can be successfully used for the targeted delivery of anti-inflammatory and other drugs for orthopedic and cardiovascular applications. The delivery of localized therapies to other organs of the body is also under intense investigation and is expected to deliver breakthrough solutions for the treatment of many chronic diseases including Cancer. MIVT believes that the future treatment of diseases will rely heavily on the novel HAp-based drug delivery systems and novel polymer-free drug delivery systems developed by the company. E[acute accent]Prof. Troczynski also reviewed the HAp-based products' demonstrated ability to maintain structural and functional integrity and performance through deployment in the body and during long-term use following implantation. E[acute accent]The Department of Materials Science and Engineering at the University of Washington is recognized as one of the world's top providers of education in the materials field. "The direct interaction of faculty and research staff from different universities and scientific institutions is a powerful mechanism for the advancement of our fundamental and applied knowledge of complex biomaterials systems," said Prof. Troczynski. "The proximity of the Department of Materials Science and Engineering to our laboratories at UBC in Vancouver makes such contacts particularly attractive to both organizations. We have hosted the MSE researchers and faculty in the past and we will benefit from this continuous learning process as we develop new applications for our coating and drug delivery technologies in the important cardiovascular and orthopedic fields."

E[acute accent]About MIV Therapeutics Inc.

E[acute accent]MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.